Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. - Wikidata - awgldk - TriplyDB

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

http://www.wikidata.org/entity/Q43153489

about

Advances in the management of sepsis and the understanding of key immunologic defects Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.Prospective monitoring of cefepime in intensive care unit adult patients Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.Antimicrobial stewardship.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Ceftaroline for complicated skin and skin-structure infections.Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.Current concepts in the prevention and treatment of ventilator-associated pneumonia.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-negative Bacteria in the Murine Thigh Infection Model.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?A model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU.Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.Implementing extended-infusion cefepime as standard of care in a children's hospital: a prospective descriptive study.Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients.Population pharmacokinetics of cefquinome in pigs.Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients

P2860

Q26865386-F9FCC4D5-DE49-41C6-9556-BF14CFEFFCD7 Q33676227-E0DE3DBE-AB3A-4461-AAA5-8983214F2348 Q33919165-E2ECB85B-C518-4AB6-8C72-8564EC22102B Q34003193-5677D5AE-F662-4FAF-9C4E-3B6425E39B69 Q34228050-9027AD76-6FF7-4986-A9B9-8D441B533F19 Q34274190-6A8D6599-49EC-42FB-8DB2-9F9EA8035905 Q35569189-8A37BD44-A07E-4732-AC68-7285C0951746 Q35908084-026D46AD-DDEE-4258-A78D-963E15148B18 Q35960873-48C588B0-005F-499B-A553-7736B85877EA Q36969880-2BECE58A-2D6A-4883-9CBF-37109DBF67BF Q37516599-34907415-AE23-4007-A3A3-D90B862B4326 Q37643682-D38A0608-9567-4DFE-928E-4C2948871465 Q37656243-EF554B4F-BFD0-433B-B84A-DCF0D329CA65 Q37733561-F3D709AF-5BF2-4B07-B579-35EF10938C84 Q37771799-5C7E784A-4215-4388-A6BC-BCBAFFE99714 Q37867261-9D5456A8-C855-47B9-82F4-698987E8D3A4 Q38073197-85720FD4-7E06-4E9C-BE88-9D37BB728E0C Q38100704-BF31698E-FB39-44FD-AAB5-E53592A1A721 Q38138835-51D23985-94C9-4B46-AE7B-63F132CB266C Q38165138-6BB25043-980B-4F52-B379-643114B68C9E Q38313276-9563C9DA-472B-4187-9B55-D916D35179E4 Q38605133-3E0419F8-B1F9-43FC-984C-AD601EBFAD7A Q38672016-BB4D1E5D-81B1-4122-A17E-CC2D8870460C Q38741453-C4E99B66-12A1-424D-AC94-A7AF4774C9A3 Q39344408-3B665945-42B6-43D2-BD19-2703D40643BD Q39721085-8B150E48-EC7F-4AC7-8AFF-D41801C3F483 Q40073466-8F8FFB93-C260-4FB5-814B-E2FA736E61F1 Q40087256-740A2288-9DCA-4490-ACCC-10DF8C03AAFB Q40375664-77A22828-08F1-4194-93A8-BB47B26137A4 Q41538340-52DA182D-44E8-45E7-95BE-575551373A4C Q41564878-A5E4A7C9-9A2C-40F1-B875-C2FDCE7D64C2 Q42259839-60DDFE91-3359-4CDA-8C46-A025BD2B5CCC Q49064586-6384D90C-457A-431D-926B-00904CBD2610 Q51014621-8D5E8DF1-CAAA-470F-93FB-FFE4FCBFABEB Q51295882-9F77E399-02B8-4CF8-90F7-9088DA6D4949 Q55514103-6477E6C3-8AF9-4832-9E34-8859680F7DCD Q58701649-F612E61D-1ABD-4977-9E2A-D15BF08C15BA

P2860

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

http://www.wikidata.org/entity/Q43153489

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Population pharmacokinetics of ...... ntilator-associated pneumonia.

@en

Population pharmacokinetics of ...... ntilator-associated pneumonia.

@nl

type

label

Population pharmacokinetics of ...... ntilator-associated pneumonia.

@en

Population pharmacokinetics of ...... ntilator-associated pneumonia.

@nl

prefLabel

Population pharmacokinetics of ...... ntilator-associated pneumonia.

@en

Population pharmacokinetics of ...... ntilator-associated pneumonia.

@nl

P1433

Q43153489-A39A7159-6B5A-4207-A6F3-29F26141B681

P1476

Q43153489-9C6B6F05-0874-4F5F-BFC7-62BB9AC749CA

P2093

Q43153489-1D188541-4118-4DE0-9479-1004C6AC2719

Q43153489-9C2541FE-0484-4E24-899D-54ACDFAD252D

Q43153489-CA17DC77-4489-4C01-AFE3-E71DF15B482D

Q43153489-D3FBE417-0117-494D-9F82-89DFD4FB9CE7

Q43153489-DBAB3F6C-6DBE-4240-8AC7-BE2B5E07AE76

P2860

Q43153489-0361D808-6A09-4F7E-AAD7-5F6569120C8F

Q43153489-0EEA2D71-2301-4CAC-B9D6-965B480FA41D

Q43153489-129EC9DA-EE5E-425C-9B99-46E5A5683964

Q43153489-23E6FDD6-069E-4BAD-816C-34CF39FF272A

Q43153489-2886A898-B13C-422C-AB8A-EC5DFA5BA6BC

Q43153489-2991598E-1846-482C-A1C3-118B59F51FAE

Q43153489-2A365940-FA59-47EE-8644-F9F6D5350205

Q43153489-31153A2A-CCCE-4B61-A28A-A6F6DF33752F

Q43153489-345F28B5-BBE0-402D-A153-84739692DE78

Q43153489-355C508D-2FE8-4D5C-92B5-45166BDAC61A

P304

Q43153489-2C67E327-C9BB-4020-9854-EAA49485889D

P31

Q43153489-CF3EC076-DD58-4434-8FDA-FAE358CDA1B0

P356

Q43153489-68D858A8-5CB7-4986-9883-F9D5647C807B

P407

Q43153489-8E7A491B-17EE-4F12-9256-EC891244B2CE

P433

Q43153489-C652090E-252B-4B47-B03F-4E561A042F14

P478

Q43153489-CEBBC076-3103-42CA-8ED3-A3655998BC67

P50

Q43153489-AB1B50D0-BD5B-44E0-B113-72C8E1FAF804

Q43153489-B760539C-FEC8-46B5-8BAD-81A4738AAD38

P577

Q43153489-A47EB098-E796-4E24-A686-3D560CADF051

P698

Q43153489-B5F9B409-E00B-4988-8A87-141712888945

P921

Q43153489-470C2A75-A011-4505-9259-61F0F54FEAA0

Q43153489-E1ED4CE2-B905-48DF-AB7D-C866C551437C

P932

Q43153489-F012A8DA-069D-4EF5-9249-10A534171CD4

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population pharmacokinetics of ...... ntilator-associated pneumonia.

@en

P2093

Anthony M Nicasio

http://www.w3.org/2001/XMLSchema#string

Aryun Kim

http://www.w3.org/2001/XMLSchema#string

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

Jared L Crandon

http://www.w3.org/2001/XMLSchema#string

Joseph L Kuti

http://www.w3.org/2001/XMLSchema#string

P2860

APACHE II: a severity of disease classification system

Prediction of creatinine clearance from serum creatinine

Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.

Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing

Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.

The current state of multidrug-resistant gram-negative bacilli in North America.

Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

P304

1476-1481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01141-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Sheryl A. Zelenitsky

Robert E Ariano

P577

2009-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19188394

http://www.w3.org/2001/XMLSchema#string

P921

P932

2663089

http://www.w3.org/2001/XMLSchema#string